MedTrace Logo

Dose Dependent Steroid Injections

NCT07494136 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-03-27

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, to evaluate the efficacy of interlaminar steroid injections at improving quality of life and function in lumbar radiculopathy at varying doses, and to evaluate difference in efficacy between triamcinolone and dexamethasone interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, with the overarching hypotheses that there is no difference in reported pain reduction, quality of life, or function among patients receiving low, moderate, or high doses, and no difference in reported pain reduction between triamcinolone and dexamethasone.

Conditions

  • Lumbar Radiculopathy
  • Sciatica
  • Back Pain With Radiation

Interventions

DRUG

Triamcinolone 10 Mg/mL Injectable Suspension

A single 10 mg Triamcinolone interlaminar lumbar epidural steroid injection administered in the lumbar spine.

DRUG

Triamcinolone 40 Mg/mL Injectable Suspension

A single 40 mg Triamcinolone interlaminar lumbar epidural steroid injection administered in the lumbar spine.

DRUG

Triamcinolone 80 Mg/mL Injectable Suspension

A single 80 mg Triamcinolone interlaminar lumbar epidural steroid injection administered in the lumbar spine.

DRUG

Dexamethasone 2 MG

A single 2 mg Dexamethasone interlaminar lumbar epidural steroid injection administered in the lumbar spine.

DRUG

Dexamethasone 4mg

A single 4 mg Dexamethasone interlaminar lumbar epidural steroid injection administered in the lumbar spine.

DRUG

Dexamethasone 8 MG

A single 8 mg Dexamethasone interlaminar lumbar epidural steroid injection administered in the lumbar spine.

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Seyed A mostoufi, MD · Christine E. Lynn Rehabilitation Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-05-31
Completion
2027-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07494136 on ClinicalTrials.gov